following a full submission:
treosulfan (Trecondi®) is accepted for restricted use within NHSScotland.
Indication under review: in combination with fludarabine as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non-malignant diseases, and in paediatric patients older than one month with malignant diseases.
SMC restriction: in patients with malignant disease for whom a reduced intensity conditioning regimen is required.
Treosulfan plus fludarabine was non-inferior to another reduced intensity conditioning regimen for event-free survival (EFS) in adults undergoing alloHSCT for acute myeloid leukaemia (AML) or myelodysplatic syndrome (MDS) who were at increased risk with standard conditioning regimens.
Download detailed advice788KB (PDF)
Medicine details
- Medicine name:
- treosulfan (Trecondi)
- SMC ID:
- SMC2527
- Indication:
In combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non-malignant diseases, and in paediatric patients older than one month with malignant diseases.
- Pharmaceutical company
- Medac UK
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 12 June 2023